It has just been announced that there are now two new additional sites added to the Early/Expanded Access Program for Enzalutamide (MDV3100). The program is technically a clinical trial designed to monitor MDV-3100’s safety in men with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
This means that there are now a total of 16 states which have an Early/Expanded Acess Program and additional sites are still expected.
In this trial there are no placebos and no cost for the MDV3100/enzalutamide Please check with the trial site for any other costs which you might be required to pay.
Basic Eligibility Criteria:
CRPC/HRPC – on hormone therapy with progressive disease
3 weeks since Zytiga (abiraterone)
NO small cell or neuroendocrine features
Previously treated with Taxotere (docetaxel)
No brain metastases
HGB 9.0 or higher
No history of stroke or seizure
No significant cardiovascular disease
If you think you fit the above Criteria, contact one of the sites. below for further criteria and screening.
The two new sites are:
Stanford University Cancer Center
Contact: Denise Haas (650) 736-1252
Pal Alto, CA 94304